CeGaT

Executive Summary

CeGaT GmbH, headquartered in Tübingen, Germany, is a premier genetic diagnostics and next-generation sequencing (NGS) service provider founded in 2009. The company operates through two core units: Genetic Diagnostics, aiding physicians in diagnosing rare and tumor diseases, and Research & Pharma Solutions, offering sequencing services to pharmaceutical companies and academic researchers. Accredited to CAP/CLIA and ISO standards, CeGaT is recognized as a global leader in genetic analysis, leveraging deep expertise in exome, genome, and transcriptome sequencing. Its strong foothold in both clinical diagnostics and research partnerships positions it as a critical enabler of precision medicine. CeGaT's growth is driven by increasing demand for genomic testing in rare diseases and oncology, alongside expanding collaborations with pharma for biomarker discovery and companion diagnostics. The company benefits from its advanced NGS infrastructure and stringent quality certifications, which facilitate client trust and repeat business. While the diagnostics market is competitive, CeGaT's specialization and accreditation open doors to premium service contracts. Upcoming catalysts include novel test launches and strategic alliances, which could further solidify its market position. Overall, CeGaT exemplifies a high-quality, niche diagnostics provider with steady growth prospects.

Upcoming Catalysts (preview)

• Q3 2026Launch of comprehensive liquid biopsy panel for early cancer detection75% success
• Q2 2026Major pharma partnership for pharmacogenomics and drug development services65% success
• Q4 2026Introduction of CE-IVDR certified rare disease diagnostic panel80% success